



## Uwe Gottschalk appointed as Board Observer

**June 15<sup>th</sup>, 2023** - Axxam S.p.A. (Milan/Italy), an innovative Partner Research Organization (iPRO) announced the appointment of Dr. Uwe Gottschalk as Board Observer.

Uwe Gottschalk, presently an Operating Partner at Keensight Capital, will participate as an Observer in the Board of Directors and Steering Committee Meetings, bringing extensive expertise, vision and international contacts.

Uwe Gottschalk's appointment follows a very successful and respected, 30-year, career in industrial biotechnology and bioprocessing, most recently as Chief Scientific Officer (CSO) of Lonza Group, the world's largest company for biologics contract development and manufacturing, and Group Vice President at Sartorius Stedim Biotech, where he had global responsibility for bioseparation process technologies. Dr. Gottschalk was a head lecturer at the University of Duisburg-Essen, and also lectured at the École Polytechnique Fédérale de Lausanne. Uwe is a valued member of several associations connected to the pharmaceutical industry, such as the Society for BioChromatography and Nanoseparations, and the American Chemical Society. He sits on the editorial advisory boards of various journals, including Pharmaceutical Bioprocessing, Genetic Engineering News and BioPharm International and is a renowned author of impactful books and articles in the space. In 2021 he received the Bioprocessing Lifetime Achievement Award at the Asia Biologics Manufacturing Conference.

**Uwe Gottschalk** said: *"I am very happy to join Axxam and to be part of this great team. This position will allow me to support the dynamic field of discovering new therapeutic drugs and active ingredients. I look forward to translating my past experiences to contributions ensuring the significant growth of Axxam and to enable our clients and partners to generate innovative solutions across all life sciences"*.

**Stefan Lohmer, CEO of Axxam** stated: *"We are very excited to have Uwe participating to our meetings. Uwe's domain-specific leadership and operational experience will allow him to contribute to the scientific and business evolution of Axxam. Continuing our 20-year Axxam journey, it is our goal to be the best-in-class, most innovative, biology-centric integrated research company globally, covering all steps from target assessment to lead discovery."*

\*\*\*

### About Axxam

Axxam is an innovative Partner Research Organization (iPRO) providing integrated discovery services across the life sciences industries. Axxam is headquartered in the Milan area (Italy), with other research laboratories in Naples (Italy) as well as Constance (Germany) and business offices in Cambridge (USA), Copenhagen (Denmark) and Basel (Switzerland). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation, over all therapeutic areas and target classes. Axxam's services include assay development, high-throughput screening, hit validation and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, please visit [www.axxam.com](http://www.axxam.com)